# RIMS2

## Overview
RIMS2 is a gene that encodes the protein regulating synaptic membrane exocytosis 2, which is a crucial component in the process of synaptic vesicle exocytosis. This protein is part of the Rab3-interacting molecules (RIMs) family, which are essential for the proper functioning of presynaptic active zones in neurons. As a multi-domain scaffolding protein, RIMS2 plays a significant role in the docking, priming, and fusion of synaptic vesicles with the presynaptic membrane, thereby facilitating neurotransmitter release (Wu2023The; KIM2013Association). It interacts with various proteins, including voltage-gated calcium channels, to ensure efficient synaptic transmission. RIMS2 is expressed in several tissues, including the brain, retina, and pancreas, highlighting its importance in diverse physiological processes (Wu2023The). Mutations and alterations in the RIMS2 gene have been linked to several diseases, such as colorectal cancer, Parkinson's disease, and congenital stationary night blindness, underscoring its clinical significance (Li2023Aberrant; Almutairi2020Congenital; Liu2021Genomewide).

## Structure
RIMS2 is a protein involved in synaptic vesicle exocytosis and is characterized by its complex molecular structure. It contains multiple domains, including C2 domains, which are known for their calcium-binding capabilities, and PDZ domains, which are crucial for facilitating protein-protein interactions. These domains contribute to the protein's role in synaptic function by enabling it to interact with other proteins and respond to calcium signals.

The protein may undergo post-translational modifications, such as phosphorylation, which can influence its activity and interactions. Phosphorylation is a common modification that can regulate the function of proteins involved in signaling pathways, including those in synaptic transmission.

RIMS2 also exhibits functional diversity through the presence of several splice variant isoforms. These isoforms result from alternative splicing, a process that allows a single gene to produce multiple protein variants with potentially different functions or regulatory properties. The existence of these isoforms suggests that RIMS2 can adapt to various cellular contexts and demands, contributing to its versatility in synaptic processes. The combination of its structural domains, post-translational modifications, and splice variants underscores the complexity and adaptability of RIMS2 in neuronal communication.

## Function
The RIMS2 gene encodes a protein that plays a critical role in synaptic vesicle exocytosis, a process essential for neurotransmitter release in neurons. RIMS2 is part of the Rab3-interacting molecules (RIMs) family, which are presynaptic active zone proteins involved in the docking, priming, and fusion of synaptic vesicles with the presynaptic membrane (Wu2023The; KIM2013Association). This protein acts as a scaffold within the cytomatrix of the active zone, interacting with other proteins such as RIM-binding proteins, ELKS/CAST, and Munc13-1 to organize the protein network necessary for efficient synaptic transmission (Wu2023The).

RIMS2 is crucial for the localization and functional regulation of voltage-gated calcium channels (VGCCs) at synaptic terminals, which are vital for neurotransmitter release. It recruits VGCCs to the active zone, affecting the number and function of calcium channels, thereby synchronizing calcium influx and vesicle release (Wu2023The). In the brain, RIMS2 is highly expressed in cerebellar cortical neurons, particularly Purkinje cells, and is also present in the retina and pancreas, indicating its role in synaptic function across various tissues (Wu2023The).

## Clinical Significance
Mutations and alterations in the RIMS2 gene have been implicated in several diseases and conditions. In colorectal cancer (CRC), RIMS2 expression is often silenced due to promoter hypermethylation, which is associated with poor disease-free survival in patients. This hypermethylation is linked to KRAS mutations and differentiation in CRC, suggesting that RIMS2 methylation could serve as a prognostic biomarker (Li2023Aberrant).

In Parkinson's disease (PD), genetic variants in the RIMS2 locus are significantly associated with the progression to Parkinson's Disease Dementia (PDD). The lead variant rs182987047 in the RIMS2 locus is linked to a higher hazard ratio for progression to PDD, indicating a role in cognitive decline (Liu2021Genomewide).

RIMS2 mutations have also been associated with congenital stationary night blindness (CSNB), particularly in a syndromic form that includes neurodevelopmental and pancreatic involvement. These mutations disrupt synaptic membrane exocytosis, affecting rod photoreceptors and other cells (Almutairi2020Congenital).

In tardive dyskinesia (TD), a frameshift variant in RIMS2 has been identified, suggesting a potential role in TD susceptibility. This variant is more common in severe TD patients and may disrupt RIMS2's function as a scaffolding protein, affecting synaptic protein exocytosis (Alkelai2019New).

## Interactions
RIMS2, a protein involved in synaptic vesicle exocytosis, participates in several critical interactions with other proteins. It is a member of the Rab3-interacting molecule family, which are multi-domain scaffolding proteins essential for neurotransmitter release. RIMS2 interacts with Rab3, a small GTPase involved in synaptic vesicle trafficking, and Munc13, a protein crucial for synaptic vesicle priming and fusion (Wu2023The). These interactions facilitate the docking, priming, and fusion of synaptic vesicles with the presynaptic membrane, which are essential steps in neurotransmitter release (Wu2023The).

RIMS2 also interacts with synaptic vesicle proteins and presynaptic ion channels, such as voltage-gated calcium channels (VGCCs). It plays a role in anchoring these calcium channels to release sites, which is vital for efficient neurotransmitter release (Wu2023The). In the retina, RIMS2 is involved in maintaining synaptic connections at photoreceptor ribbon synapses, acting as a modulator of Ca2+ channels rather than being involved in vesicle priming (Mechaussier2020Loss).

Additionally, RIMS2 has been identified as a binder to the PDZ-binding motif of the West Nile Virus NS5 protein, although this interaction does not interfere with viral replication, suggesting a potential role in other steps of the viral cycle (Giraud2021Role).


## References


[1. (Almutairi2020Congenital) Faris Almutairi, Nawaf Almeshari, Khabir Ahmad, Moustafa S. Magliyah, and Patrik Schatz. Congenital stationary night blindness: an update and review of the disease spectrum in saudi arabia. Acta Ophthalmologica, 99(6):581–591, December 2020. URL: http://dx.doi.org/10.1111/aos.14693, doi:10.1111/aos.14693. This article has 11 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1111/aos.14693)

[2. (Wu2023The) Shanshan Wu, Jiali Fan, Fajuan Tang, Lin Chen, Xiaoyan Zhang, Dongqiong Xiao, and Xihong Li. The role of rim in neurotransmitter release: promotion of synaptic vesicle docking, priming, and fusion. Frontiers in Neuroscience, April 2023. URL: http://dx.doi.org/10.3389/fnins.2023.1123561, doi:10.3389/fnins.2023.1123561. This article has 3 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fnins.2023.1123561)

[3. (KIM2013Association) KI-TACK KIM, JONG SEOK LEE, BYOUNG WOOK LEE, HOSIK SEOK, HYE SOOK JEON, JUN HO KIM, and JOO-HO CHUNG. Association between regulating synaptic membrane exocytosis 2 gene polymorphisms and degenerative lumbar scoliosis. Biomedical Reports, 1(4):619–623, May 2013. URL: http://dx.doi.org/10.3892/br.2013.101, doi:10.3892/br.2013.101. This article has 12 citations and is from a peer-reviewed journal.](https://doi.org/10.3892/br.2013.101)

[4. (Alkelai2019New) Anna Alkelai, Lior Greenbaum, Erin L. Heinzen, Evan H. Baugh, Alexander Teitelbaum, Xiaolin Zhu, Rael D. Strous, Pavel Tatarskyy, Clement C. Zai, Arun K. Tiwari, Maria Tampakeras, Natalie Freeman, Daniel J. Müller, Aristotle N. Voineskos, Jeffrey A. Lieberman, Shannon L. Delaney, Herbert Y. Meltzer, Gary Remington, James L. Kennedy, Ann E. Pulver, Emma P. Peabody, Deborah L. Levy, and Bernard Lerer. New insights into tardive dyskinesia genetics: implementation of whole-exome sequencing approach. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 94:109659, August 2019. URL: http://dx.doi.org/10.1016/j.pnpbp.2019.109659, doi:10.1016/j.pnpbp.2019.109659. This article has 9 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.pnpbp.2019.109659)

[5. (Li2023Aberrant) Xuan Li, Du Cai, Yaoyi Huang, Yumo Xie, Dingcheng Shen, Ze Yuan, Xiaoxia Liu, Meijin Huang, Yanxin Luo, Huichuan Yu, and Xiaolin Wang. Aberrant methylation in neurofunctional gene serves as a hallmark of tumorigenesis and progression in colorectal cancer. BMC Cancer, April 2023. URL: http://dx.doi.org/10.1186/s12885-023-10765-x, doi:10.1186/s12885-023-10765-x. This article has 4 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/s12885-023-10765-x)

[6. (Giraud2021Role) Emilie Giraud, Chloé Otero del Val, Célia Caillet-Saguy, Nada Zehrouni, Cécile Khou, Joël Caillet, Yves Jacob, Nathalie Pardigon, and Nicolas Wolff. Role of pdz-binding motif from west nile virus ns5 protein on viral replication. Scientific Reports, February 2021. URL: http://dx.doi.org/10.1038/s41598-021-82751-x, doi:10.1038/s41598-021-82751-x. This article has 9 citations and is from a peer-reviewed journal.](https://doi.org/10.1038/s41598-021-82751-x)

[7. (Mechaussier2020Loss) Sabrina Mechaussier, Basamat Almoallem, Christina Zeitz, Kristof Van Schil, Laila Jeddawi, Jo Van Dorpe, Alfredo Dueñas Rey, Christel Condroyer, Olivier Pelle, Michel Polak, Nathalie Boddaert, Nadia Bahi-Buisson, Mara Cavallin, Jean-Louis Bacquet, Alexandra Mouallem-Bézière, Olivia Zambrowski, José Alain Sahel, Isabelle Audo, Josseline Kaplan, Jean-Michel Rozet, Elfride De Baere, and Isabelle Perrault. Loss of function of rims2 causes a syndromic congenital cone-rod synaptic disease with neurodevelopmental and pancreatic involvement. The American Journal of Human Genetics, 106(6):859–871, June 2020. URL: http://dx.doi.org/10.1016/j.ajhg.2020.04.018, doi:10.1016/j.ajhg.2020.04.018. This article has 22 citations.](https://doi.org/10.1016/j.ajhg.2020.04.018)

[8. (Liu2021Genomewide) Ganqiang Liu, Jiajie Peng, Zhixiang Liao, Joseph J. Locascio, Jean-Christophe Corvol, Frank Zhu, Xianjun Dong, Jodi Maple-Grødem, Meghan C. Campbell, Alexis Elbaz, Suzanne Lesage, Alexis Brice, Graziella Mangone, John H. Growdon, Albert Y. Hung, Michael A. Schwarzschild, Michael T. Hayes, Anne-Marie Wills, Todd M. Herrington, Bernard Ravina, Ira Shoulson, Pille Taba, Sulev Kõks, Thomas G. Beach, Florence Cormier-Dequaire, Guido Alves, Ole-Bjørn Tysnes, Joel S. Perlmutter, Peter Heutink, Sami S. Amr, Jacobus J. van Hilten, Meike Kasten, Brit Mollenhauer, Claudia Trenkwalder, Christine Klein, Roger A. Barker, Caroline H. Williams-Gray, Johan Marinus, Jacobus J. van Hilten, and Clemens R. Scherzer. Genome-wide survival study identifies a novel synaptic locus and polygenic score for cognitive progression in parkinson’s disease. Nature Genetics, 53(6):787–793, May 2021. URL: http://dx.doi.org/10.1038/s41588-021-00847-6, doi:10.1038/s41588-021-00847-6. This article has 90 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/s41588-021-00847-6)